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RMethods: Sixty-six patients with DCM were followed-up for 12 months after initi-
ation of medical treatment including carvedilol, ramipril (candesartan if ramipril
was not tolerated), spironolactone and furosemide. Tenascin-C and NT pro-BNP
measurements and transthoracic echocardiography was performed at baseline and at
12 months.
Results: At 12 months, a signiﬁcant improvement in NYHA class (2.570.6 vs.
1.870.5, p<0.0001), left ventricular end-diastolic volume (21747 vs. 203  48,
p<0.0001), left ventricular ejection fraction (29.15.5 vs. 30.93.8, p<0.0001), NT
pro-BNP (2019558 vs. 1462805, p<0.0001) and Tenascin-C (7619 vs. 4828,
p<0.0001) values were observed, when compared with baseline. Importantly,
decrease in Tenascin-C values were correlated with increase in LVEF. Tenascin-C
(odds ratio (OR): 1.896, <95% conﬁdence interval (CI) 1.543-2.670; p¼0.02), DM
(OR: 2.456, <95% Cl 1.987-3.234; p¼0.01) and HT (OR: 2.106, <95% Cl 1.876-
2.897; p¼0.03) were independent predictors of mortality in patients with DCM.
Conclusıon: Reverse ventricular remodeling obtained with carvedilol, ramipril/
candesartan and spironolactone is associated with decreases in LVEDV, LVESV,
Tenascin-C levels and NT pro-BNP levels. Consequently, Tenascin-C may be used to
evaluate reverse remodeling in patients with DCM.JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POST
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Introductıon: MicroRNAs (miRNAs) are small, endogenous and non-coding RNAs
that are 21-25 nucleotides in length. Recent studies have demonstrated the role of
miRNAs as potential biomarkers in various disorders. The aim of this study was to
quantitatively evaluate expression levels of miRNAs with functional differences in
patient with congestive heart failure (CHF).
Methods: In our study, 20 clinically stable (NYHA II) and 22 decompansated (NYHA
III and IV) systolic CHF (EF <%40) patients and 15 healthy controls were enrolled.
Whole genome miRNA proﬁling was done and dysregulated miRNAs were detected
with microarray method in CHF patients compared to healthy controls.
Results: Microarray proﬁling showed serum miR-21, miR-4278, miR-650, miR-
744star, miR-516-5p, miR-1292, miR-182, miR-1228, miR-595, miR-663b, miR-
1296, miR-1825, miR-299-3p, miR-662 miR-122-star, miR-3148, miR-518e-star,
miR-2054 as up regulated, and serum miR-129-3p, miR-3155, miR-3175, miR-583,
miR-568, miR-30d, miR-200a-star, miR-1979, miR-371-3p, miR-155-star, miR-502-
5p as down regulated in CHF patients with a signiﬁcant increase of >1.2 fold
(p<0.05) (Figure). There was no association between these miRNAs and important
clinical prognostic parameters such as NYHA class (p>0.05), pro-BNP (p>0.05) and
high sensitive C-reactive protein (hs-CRP) (p>0.05).
Conclusıon: The present study indicated that patients with heart failure exhibit
different serum miRNA proﬁle compared to healthy controls.PP-061
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Aim: Heart failure is a cardiovascular disease that is caused by impaired left
ventricular systolic and diastolic function. Ischemic and non-ischemic cardiomyopa-
thies are the most common cause of heart failure. Its mortality is high despite to the
new treatment regimens. Along with dilatation left ventricul, right ventricular changes,
particularly structural and functional, occurs in the advanced heart failure. Assessment
of the right ventricular function is very important as it has prognostic signiﬁcance in
mortality and morbidity. Although right ventricle is often neglected due to complexity
in the assessment of function and structure, provides valuable information on the
current practice. Impaired parameters used in the assessment of right ventricularERS C105
Demographic properties of the patients
Parameters
Patients who
died
Patients who
survived p
Male n (%) 15 (83,3) 89 (78,1) 0,612
Age (meanSD) 568 6010 0,049
LV EF (%) 242 274 <0,001
Duration of heart failure (year) 3,81,7 4,63,6 0,869
NYHA functional class, n (%) 13 (72,3) 38 (33,4) 0,001
Ischemic etiology of heart
failure, n (%)
8 (44,4) 80 (70,2) 0,031
Rervascularization, n (%) 7 (38,9) 61 (53,5) 0,249
CRT-D implantation, n (%) 6 (33,3) 29 (25,4) 0,481
Diabetes Mellitus n (%) 5 (27,8) 30 (26,3) 0,896
Hyperlipidemia, n (%) 4 (22,2) 56 (49,1) 0,033
Hypertension, n (%) 7 (38,9) 66 (57,9) 0,132
Smoking, n (%) 5 (27,8) 26 (22,8) 0,644
Family history, n (%) 3 (16,7) 9 (7,9) 0,229
Chronic obstructive lung
disease, n (%)
5 (%27,8) 21 (%18,4) 0,354
Chronic renal failure, n (%) 9 (%50) 30 (26,3) 0,041
Cerebrovascular event, n (%) 2 (%11,1) 6 (%5,3) 0,334
Hepatic dysfunction, n (%) 3 (%16,7) 4 (%3,5) 0,021
Anemia, n (%) 5 (%27,8) 20 (%17,5) 0,303
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Ssystolic and diastolic function are different in ischemic and non-ischemic cardiomy-
opathy depending on the underlying cause. In the present study, we aimed to inves-
tigate right ventricular volume, diameter and systolic function in ischemic and non-
ischemic cardiomyopathy by 2D, M mode, transvalvular Doppler and tissue Doppler
echocardiography.
Method: The study population consisted of 20 ischemic (ICMP) and 21 non-ischemic
dilated cardiomyopathy (NICMP) patients with reduced left ventricular function
(EF <%35), increased left ventricular end-diastolic diameter (LVEDD >5.5 cm),
sinus ritm, less than moderate valve disease. The volume, diameter and functions of
the right and left ventricle are assessed by echocardiography. According to ischemic
and non-ischemic cardiomyopathy groups, right ventricular structure and function
were compared by using correlation analysis.
Results: Patients left ventricular systolic and diastolic functions evaluated by 2D,
mitral ﬂow Doppler and tissue Doppler echocardiography were similar in both groups.
Right ventricular longitudinal diameter in ischemic CMP was signiﬁcantly lower
when compared with non-ischemic CMP (7.56 cm, 6.66 cm p¼0.001). Mean RVEF
was comparable between the groups and 59% in NICMP while 61% in ICMP
(p¼0,346). There were no signiﬁcant differences between the groups regarding right
ventricular tricuspid ﬂow Doppler parameters. In tissue Doppler parameters, RV
lateral annulus Sm velocity was signiﬁcantly lower in ICMP than NICMP (0.11 cm/sn
vs 0.09 cm/sn; p¼0.007). TAPSE values was signiﬁcantly lover in the ICMP group
(2.29 and 2.02 p¼0.024).The other parameters assessed by tissue Doppler echocar-
diography were comparable between the groups.
Conclusıon: Reduction in right ventricular function might be different due to
hemodynamic deterioration, right ventricular infarction and also involvement of right
ventricular myopathic changes. The present study results revealed that right ventric-
ular function was signiﬁcantly decreased in ischemic heart failure when compared to
the non-ischemic group.
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Objectıve: The prognostic value of right ventricular function in heart failure is well
known. In our study, we aimed to investigate the relation of right ventricular stroke
work index (RV SWI), an invasive hemodynamic parameter of right ventricle with
prognosis of heart failure and cardiac events.
Materıals-Methods: The study followed up 132 patients admitted to our hospital
outpatient clinic between April 2011 - November 2012 with diagnosis of advanced
stage heart failure, (104 male, 28 female and age 24-81 years). The ﬁles of patients
were searched retrospectively and patients called by phone for ascertain of prognosis.
All patients’ medical history, demographic characteristics, cardiovascular risk factors,
comorbid illnesses, New York Heart Association functional class, echocardiographic
evaluations and basal right heart catheterizations performed were detected. The rela-
tion of RV SWI values with ventricular assist device insertion, heart transplantation,
cardiac resyncronisation therapy, rehospitalisation due to decompansation composite
end-points and with mortality were evaluated. Advanced stage heart failure was
deﬁned as ejection fraction < 35% with symptoms and/or signs of heart failure.
Results: In our study, 34 of 132 patients needed to rehospitalization due to cardiac
decompansation. Of these patients, 14 have died. In the patients with cardiac
decompensation right ventricular"stroke work index" 6.12.5 gr/m2/beat and 8.53.4
gr/m2/beat in the group without decompensation. Ischemic heart failure ethiology in
patients with cardiac decompensation were less frequently (p¼0.035), smoking rates
were higher (p¼0.006) and concomitant diseases were more frequently (p<0.05) than
of patients without cardiacdecompansition. Medication using frequency were signif-
icantly lower in the group with cardiac decompensation than without decom-
pansion.During 20 months follow-up, total mortality was observed in 18 (13.6%)
patients. The relation between RV SWI and mortality did not reach statistical
signiﬁcance (p¼0.773). In patients who died, mean RV SWI value was 7.53.4 g/m2/
beat, those who survived had RV SWI mean value 8.03.4 gr/m2/beat. The left
ventricular ejection fraction (p<0.001) and right ventricle systolic diameter (p<0.001)
had statistically signiﬁcant relation with mortality. In patients who survived without
cardiac events RV SWI value was signiﬁcantly different from those who survived with
cardiac events (p¼0.003), indicating that decreased RV SWI is associated with
increased cardiac event rates among patients with advanced stage heart failure.
Conclusıon: Right ventricular stroke work index is a predictor of event free survival
among patients with advanced stage heart failure. Our study did not support RV SWI
as single parameter of predictor of mortality. Risk models consisting of invasive, non-
invasive and clinical parameters should be developed for prediction of all-cause
mortality in advanced stage heart failure.C106 JACC VoPP-063
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Purpose: Ivabradine is a novel heart rate (HR) lowering agent acting by inhibiting the
If current in the sino-atrial node and has been shown to improve clinical outcomes in
chronic heart failure (HF). Inotropic stimulation with dobutamine (DOB) has been
known to increase HR and the incidence of cardiac arrhythmias in patients with HF.
However, the effects of ivabradine speciﬁcally on cardiac arrhythmias are unknown.
In this prospective study, we compared the effects of ivabradine treatment with
b blocker therapy on the increase in HR and incidence of ventricular arrhythmias
during DOB infusion using holter monitoring.
Methods: Sixty nine patients with acute decompensated HF requiring inotropic
support, LVEF <35% and in sinus rhythm were included in the present study. All
patients underwent holter recording for 6 h before the initiation of DOB infusion.
Following baseline recording, DOB was administered at incremental doses of 5, 10
and 15 mgr/kg/min, with 6-h steps. Holter monitoring was continued during 18 h of
DOB infusion. Ivabradine 7.5 mg was given at the initiation of DOB and read-
ministered at 12 h of DOB infusion in 26 patients not receiving b blocker therapy
(ivabradine group). 15 patients under b blocker therapy (b blocker group) and 28
patients not taking b blocker therapy (control group) did not receive ivabradine during
DOB infusion. Holter recordings were analyzed for change in HR, the median number
of ventricular premature contractions (VPC), ventricular couplets, episodes of non
sustained ventricular tachycardia (NSVT) and total ventricular arrhythmia for each
step of study protocol.
Results:Mean HR gradually and signiﬁcantly increased at each step of DOB infusion
in both control (8111, 9016, 9714 and 10116 respectively, p¼0.001) and
b blocker groups (7513, 8213, 8614 and 8813 respectively, p¼0.001), while
no signiﬁcant increase in HR was observed in ivabradine group (8217, 8215,
8514 and 8312 respectively, p¼0.439). The median number of VPCs, ventricular
couplets and total ventricular arrhythmia signiﬁcantly increased in ivabradine group
(p<0.001, p<0.003 and p<0.015, respectively). In control group, VPCs and total
ventricular arrhythmia increased signiﬁcantly (p<0.01 and p<0.018, respectively).
However, in b blocker group, no statistically signiﬁcant increase was found in VPCs,
couplets and total ventricular arrhythmias (Table). The incidence of NSVT did not
signiﬁcantly change in three groups.
Conclusıons: Ivabradine effectively prevents HR increase during DOB infusion,
however, it has almost no effect on DOB-induced ventricular arrhythmias. In contrast,
b blocker therapy fails to blunt DOB-induced increase in HR, but it prevents DOB-
induced increase in ventricular arrhythmias.l 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTERS
